Overview
HBIO market data
Price History
HBIO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$12.77 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -11.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.75 – $9.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $29.1M · P/B 2.17 · P/S 0.34.
Company News
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5Benzinga · Aug 12, 2026, 12:58 PM
Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.Benzinga · Aug 11, 2026, 11:05 AM
Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M EstBenzinga · Aug 11, 2026, 11:03 AM
Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M EstimateBenzinga · Aug 11, 2026, 11:02 AM
8-K filing — HARVARD BIOSCIENCE INC (HBIO)SEC EDGAR · Aug 11, 2026, 11:00 AM
Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026Benzinga · May 29, 2026, 8:15 PM